Celcuity Inc. (NASDAQ:CELC) Short Interest Update

Celcuity Inc. (NASDAQ:CELCGet Free Report) saw a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 2,490,000 shares, a growth of 10.2% from the July 31st total of 2,260,000 shares. Based on an average daily trading volume, of 386,900 shares, the short-interest ratio is currently 6.4 days.

Wall Street Analyst Weigh In

CELC has been the topic of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Celcuity in a research note on Thursday, August 15th. Leerink Partnrs upgraded shares of Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. Stifel Nicolaus lowered their target price on shares of Celcuity from $40.00 to $39.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Celcuity in a research note on Thursday, August 15th. Finally, Craig Hallum restated a “buy” rating and set a $27.00 price objective (up previously from $25.00) on shares of Celcuity in a research report on Thursday, May 16th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $28.67.

View Our Latest Stock Analysis on CELC

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Quest Partners LLC raised its holdings in Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after buying an additional 1,379 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Celcuity by 78.5% during the first quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock valued at $193,000 after acquiring an additional 3,930 shares during the last quarter. Pale Fire Capital SE boosted its holdings in shares of Celcuity by 38.4% during the fourth quarter. Pale Fire Capital SE now owns 14,409 shares of the company’s stock worth $210,000 after purchasing an additional 4,000 shares during the period. Commonwealth Equity Services LLC boosted its holdings in shares of Celcuity by 9.9% during the second quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock worth $272,000 after purchasing an additional 1,500 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its stake in shares of Celcuity by 7.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock worth $361,000 after purchasing an additional 1,600 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Trading Down 2.1 %

Shares of CELC traded down $0.34 during mid-day trading on Tuesday, reaching $15.62. The company’s stock had a trading volume of 150,089 shares, compared to its average volume of 282,866. The company has a current ratio of 14.95, a quick ratio of 14.95 and a debt-to-equity ratio of 0.54. Celcuity has a 52 week low of $8.39 and a 52 week high of $22.19. The company’s fifty day moving average price is $17.05 and its two-hundred day moving average price is $16.96. The stock has a market cap of $548.28 million, a PE ratio of -5.90 and a beta of 0.81.

Celcuity (NASDAQ:CELCGet Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same quarter in the prior year, the company earned ($0.66) earnings per share. On average, analysts predict that Celcuity will post -2.54 earnings per share for the current fiscal year.

About Celcuity

(Get Free Report)

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

Recommended Stories

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.